Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS
NCT ID: NCT04107779
Last Updated: 2020-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
279 participants
INTERVENTIONAL
2019-09-17
2020-06-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers
NCT03463837
United States Pre-Market Tobacco Application Pharmacokinetics
NCT03719391
Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers
NCT03593239
Evaluating Selected Constituents in the Exhaled Breath Samples
NCT04143256
Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers
NCT04088175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This will be a randomized, open label, parallel group study in adult smokers to be conducted at up to 5 sites in the United States. Changes in Biomarkers of Exposure (BoEs) from baseline when using four JUUL ENDS with 2 different nicotine concentrations (5%, 3%) relative to Usual Brand (UB) of combustible cigarettes and a study group abstaining from any tobacco/nicotine product use will be assessed in this study. JUUL ENDS will be used either exclusively or partially (dual-use), with subjects in the dual-use group using both JUUL 5% ENDS (choice of Virginia Tobacco (VT), Mint, Menthol or Mango flavors) and UB of combustible cigarettes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JUUL 5% Virginia Tobacco ENDS
JUUL 5% Virginia Tobacco flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS
JUUL 5%, ENDS for 6-days in confinement
JUUL 3% Virginia Tobacco ENDS
JUUL 3% Virginia Tobacco flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS
JUUL 3%, ENDS for 6-days in confinement
JUUL 5% Mint ENDS
JUUL 5% Mint flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS
JUUL 5%, ENDS for 6-days in confinement
JUUL 3% Mint ENDS
JUUL 3% Mint flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS
JUUL 3%, ENDS for 6-days in confinement
JUUL 5% Menthol ENDS
JUUL 5% Menthol flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS
JUUL 5%, ENDS for 6-days in confinement
JUUL 3% Menthol ENDS
JUUL 3% Menthol flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS
JUUL 3%, ENDS for 6-days in confinement
JUUL 5% Mango ENDS
JUUL 5% Mango flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS
JUUL 5%, ENDS for 6-days in confinement
JUUL 3% Mango ENDS
JUUL 3% Mango flavored ENDS product \[6 days\] in confinement.
Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS
JUUL 3%, ENDS for 6-days in confinement
Dual-use of JUUL 5% and UB of Combustible Cigarette
JUUL 5% Virginia Tobacco, Mint, Menthol, or Mango flavored ENDS product and usual brand of combustible cigarette \[6 days\] in confinement.
Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette
Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
UB of Combustible Cigarette
Usual brand combustible cigarette \[6 days\] in confinement.
Usual Brand of cigarettes
Continue smoking UB for 6-days in confinement.
Tobacco/Nicotine Abstention
Smoking abstention (no smoking) \[6 days\] in confinement.
Tobacco/Nicotine Abstention
No smoking for 6-days in confinement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS
JUUL 5%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS
JUUL 3%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS
JUUL 5%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS
JUUL 3%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS
JUUL 5%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS
JUUL 3%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS
JUUL 5%, ENDS for 6-days in confinement
Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS
JUUL 3%, ENDS for 6-days in confinement
Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette
Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
Tobacco/Nicotine Abstention
No smoking for 6-days in confinement.
Usual Brand of cigarettes
Continue smoking UB for 6-days in confinement.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has been a smoker for at least 12 months prior to Screening. Brief periods of non-smoking (e.g., up to \~7 consecutive days due to illness, trying to quit, participation in a study where smoking was prohibited) during the 12 months prior to Screening will be permitted at the discretion of the Investigator.
* Currently smokes an average of 10 or more king size or 100s manufactured combustible cigarettes per day, as reported at Screening.
* Cigarettes are the only tobacco product used within (≤) 30 days prior to Screening.
* Has a positive urine cotinine (≥ 200 ng/mL) at Screening.
* Has an exhaled CO \> 10 ppm at Screening.
* A female subject of childbearing potential must have been using 1 of the following forms of contraception and agree to continue using it through completion of the study:
* hormonal (e.g., oral, vaginal ring, transdermal patch, implant, or injection) consistently for at least 3 months prior to Day -2 (Check-in);
* double barrier method (e.g., condom with spermicide, diaphragm with spermicide) consistently for at least 14 days prior to Day -2 (Check-in);
* intrauterine device for at least 3 months prior to Day -2 (Check-in);
* a partner who has been vasectomized for at least 6 months prior to Day -2 (Check-in);
* abstinence beginning at least 14 days prior to Day -2 (Check-in).
* A female subject of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to Day -2 (Check-in):
* hysteroscopic sterilization;
* bilateral tubal ligation or bilateral salpingectomy;
* hysterectomy;
* bilateral oophorectomy;
* Or be postmenopausal with amenorrhea for at least 1 year prior to Day -2 (Check-in) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal status.
* Is willing to comply with the requirements of the study, including a willingness to exclusively use the JUUL products or stop smoking for the duration of the study.
* Provides voluntary consent to participate in this study documented on the signed informed consent form (ICF).
Exclusion Criteria
* Has a clinically significant abnormal finding on the physical examination, medical history, vital signs, ECG, or clinical laboratory results, in the opinion of the Investigator.
* Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).
* Has had an acute illness (e.g., upper respiratory infection, viral infection) requiring treatment (including over-the-counter (OTC) remedies) within 14 days prior to Day -2 (Check-in).
* Has a fever (\> 100.5°F) at Screening or Day -2 (Check-in).
* Has used prescription or OTC bronchodilator medication (e.g. inhaled or oral βadrenergic agonists) to treat a chronic condition within the 12 months prior to admission;
* Currently has or recently had a bladder or urinary tract infection within 30 days prior to Check-In (Day -2).
* Has a body mass index (BMI) \> 40 kg/m2 or \< 18 kg/m2 at Screening.
* Has a history of drug or alcohol abuse within 24 months prior to Day -2 (Check-in), as determined by the Investigator
* Has diabetes mellitus, asthma, or chronic obstructive pulmonary disease (COPD).
* Has a systolic blood pressure \< 90 mmHg or \> 150 mmHg, diastolic blood pressure \< 40 mmHg or \> 95 mmHg, or heart rate \< 40 bpm or \> 99 bpm at Screening.
* Has a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio \< 0.7 and FEV1 \< 80% of predicted at Screening.
* Has a post-bronchodilator FEV1 increase \> 12% and \> 200 mL from pre- to post-bronchodilator at Screening.
* Has experienced an allergic reaction following previous e-cigarette use or with exposure to any primary components of the JUUL liquids (benzoic acid, propylene glycol and glycerol).
* Has an estimated creatinine clearance \< 70 mL/minute (using the Cockcroft-Gault equation) at Screening.
* Has a positive urine screen for drugs of abuse or positive urine/breath screen for alcohol at Screening or Day -2 (Check-in).
* If female, the subject is pregnant, lactating, or intends to become pregnant during the time period from Screening through the end of study.
* Has used medications known to interact with cytochrome P450 (CYP) 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, tioconazole, tranylcypromine) within 14 days or 5 half-lives of the drug, whichever is longer, prior to Day -2 (Check-in).
* Has used nicotine-containing products other than manufactured cigarettes (e.g., ENDS, roll-your-own cigarettes, bidis, snuff, nicotine inhaler, pipe, cigar, chewing tobacco, hookah/shisha, nicotine patch, nicotine spray, nicotine lozenge, or nicotine gum) within 30 days prior to Day -2 (Check-in), except as required per protocol (e.g., the brief product trial at Screening).
* Has a prior history of JUUL product use within (≤) 30 days prior to Screening.
* Has used any prescription smoking cessation treatments, including, but not limited to, varenicline (Chantix®) or buproprion (Zyban®) within 3 months prior to Day -2 (Check-in).
* Is a self-reported puffer (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).
* Is planning to quit smoking during the study or within 3 months following Day 1, or is postponing a quit attempt in order to participate in the study.
* Negative response (i.e., unwilling to use or unable to tolerate \[e.g., experiences Adverse Events during the product trial that will prevent the subjects from continuing to use the JUUL product as judged by the Investigator\]) to any of the JUUL products at Screening.
* Has donated plasma within 7 days prior to Day -2 (Check-in).
* Has donated blood or blood products (with the exception of plasma as noted above), has had significant blood loss, or received whole blood or a blood product transfusion within 3 months prior to Day -2 (Check-in).
* Has taken any multivitamin, fish oil or biotin supplements within 48 hours prior to Check-in (Day -2).
* Has consumed any cured meats (e.g., bacon, ham, sausage, corned beef, jerky) or meats cooked at high temperatures (e.g., grilled, fried, smoked or barbecued) within 2 days prior to Check-in (Day -2).
* Has consumed any grapefruit (including grapefruit juice) eggplant or cruciferous vegetables (e.g., cauliflower, cabbage, kale, garden cress, bok choy, broccoli, brussels sprouts and similar green leaf vegetables) within 48 hours prior to Check-in (Day -2).
* Has participated in a previous clinical study for an investigational drug, device, biologic, or tobacco product within 30 days prior to Day -2 (Check-in).
* Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee of any of the study sites.
* Is or has a first-degree relative (i.e., parent, sibling, child) who is a current employee, shareholder, or is member of the board of directors of JUUL Labs Inc.
* Has previously taken part in, been withdrawn from, or has completed this study.
* Has previously been diagnosed with any form of cancer, except for basal cell or squamous epithelial carcinomas of the skin that have been resected at least 1 year prior to Screening.
* In the opinion of the Investigator, the subject should not participate in this study.
21 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Juul Labs, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Rubinstein, MD
Role: STUDY_DIRECTOR
Juul Labs, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woodland International Research Group
Little Rock, Arkansas, United States
Woodland Research Northwest
Rogers, Arkansas, United States
St. Louis Clinical Trials
St Louis, Missouri, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Endeavor Clinical Trials
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-Hayes E, Reyes-Guzman C, Jamal A, Neff L, King BA. Tobacco Product Use Among Adults - United States, 2017. MMWR Morb Mortal Wkly Rep. 2018 Nov 9;67(44):1225-1232. doi: 10.15585/mmwr.mm6744a2.
U. S. Department of Health and Human Services. The health consequences of smoking - 50 years of progress: A report of the Surgeon General. Department of Health and Human Services, Public Health Service, Office of the Surgeon General. U. S. Government Printing Office, Washington, D. C. (2014)
Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting Smoking Among Adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep. 2017 Jan 6;65(52):1457-1464. doi: 10.15585/mmwr.mm6552a1.
Gottlieb S, Zeller M. A Nicotine-Focused Framework for Public Health. N Engl J Med. 2017 Sep 21;377(12):1111-1114. doi: 10.1056/NEJMp1707409. Epub 2017 Aug 16. No abstract available.
Jensen RP, Luo W, Pankow JF, Strongin RM, Peyton DH. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015 Jan 22;372(4):392-4. doi: 10.1056/NEJMc1413069. No abstract available.
D'Ruiz CD, Graff DW, Robinson E. Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and tolerability in adult smokers following partial or complete substitution of cigarettes with electronic cigarettes. BMC Public Health. 2016 Jul 11;16:543. doi: 10.1186/s12889-016-3236-1.
McNeill A et al. E-cigarettes: An Evidence Update. A report commissioned by Public Health England. Available at: https://www.gov.uk/government/uploads/system/uploads/ attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf (Aug 2015).
Polosa R, Morjaria J, Caponnetto P, Caruso M, Strano S, Battaglia E, Russo C. Effect of smoking abstinence and reduction in asthmatic smokers switching to electronic cigarettes: evidence for harm reversal. Int J Environ Res Public Health. 2014 May 8;11(5):4965-77. doi: 10.3390/ijerph110504965.
Tanner JA, Tyndale RF. Variation in CYP2A6 Activity and Personalized Medicine. J Pers Med. 2017 Dec 1;7(4):18. doi: 10.3390/jpm7040018.
HIPAA Privacy Rule. Information for Researchers. De-identifying Protected Health Information Under the Privacy Rule. U.S. Department of Health and Human Services. NIH (Feb 2007). Available at: http://privacyruleandresearch.nih.gov/pr_08.asp#8a.
Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2012 Jan;14(1):75-8. doi: 10.1093/ntr/ntr137. Epub 2011 Oct 24. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROT-00030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.